Montenaaf 10 mg (Tablet)

Title

• Montenaaf 10 mg Tablet

Categories

• Medicine
• Healthcare
• Pharmacology

Indications

• Prophylaxis and chronic treatment of asthma
• Acute prevention of Exercise-Induced Bronchoconstriction (EIB)
• Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis

Pharmacology

• Selective and orally active leukotriene receptor antagonist
• Inhibits the cysteinyl leukotriene receptor (CysLT1)
• Correlated with the pathophysiology of asthma & allergic rhinitis
• Contributes to signs and symptoms of asthma
• Released from various cells including mast cells and eosinophils

Dosage & Administration

• Adult dosage: Montelukast 10 mg tablet once daily
• Pediatric dosage: Varies based on age
• Use in pediatric patients aged 6 months to 14 years
• No dosage adjustment required for hepatic or renal insufficiency
• Similar pharmacokinetic profile in elderly adults

Interaction

• Administered with other therapies for asthma without increase in adverse reactions
• Did not have clinically important effects on the pharmacokinetics of specified drugs
• Used concomitantly with a wide range of commonly prescribed drugs without adverse interactions
• Effects of phenobarbital on montelukast metabolism

Contraindications

• Hypersensitivity to any component of the product

Side Effects

• Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection
• Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders
• Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor

Pregnancy & Lactation

• Crosses placenta in rats and rabbits
• No adequate and well-controlled studies in pregnant women
• Use during pregnancy only if clearly needed
• Caution advised when given to a nursing mother due to excretion in human milk

Precautions & Warnings

• Not indicated for use in the reversal of bronchospasm in acute asthma attacks
• Appropriate rescue medication should be available
• Can be continued during acute exacerbations of asthma
• Should not be abruptly substituted for inhaled or oral corticosteroids
• Not to be used as monotherapy for the treatment of exercise induced bronchospasm
• Avoidance of aspirin or non-steroidal anti-inflammatory agents in patients with known aspirin sensitivity

Overdose Effects

• No adverse experiences in majority of overdosage reports
• Usual supportive measures recommended in the event of overdose

Therapeutic Class

• Leukotriene receptor antagonists

Storage Conditions

• Store in cool & dry place below 30°C
• Protect from light & moisture
• Keep out of reach of children

Chemical Structure

• Molecular Formula: C35H36ClNO3S

Common Questions

• What is Montenaaf 10 mg Tablet?
• What is Montenaaf 10 mg Tablet used for?
• How soon can the effect be observed?
• How long does the effect last?
• Should it be taken empty stomach?
• What if a dose is missed?
• Pregnancy warnings for Montenaaf 10 mg Tablet
• General Instructions

Common Questions & Answers

• Montenaaf 10 mg Tablet is a selective and orally active leukotriene receptor antagonist
• Commonly used to treat asthma or allergic rhinitis
• Effect can be observed after 1-3 hours of administration
• Effect lasts for an average duration of 24 hours
• May be taken with or without food as prescribed
• Instructions for missed dose, pregnancy warnings, and general use

Usability Features

• Easy breathing by blocking leukotrienes
• Not a fast-acting rescue medicine for asthma attacks
• Not to be used in the reversal of bronchospasm

Medical Precautions

• Appropriate rescue medication should be available
• Exercise caution in sudden substitution for inhaled or oral corticosteroids
• Avoidance of aspirin or non-steroidal anti-inflammatory agents in patients with aspirin sensitivity

Age-specific Dosage

• Specific dosages for adults, adolescents, and pediatric patients of different age groups

Safety Profiling

• Similar safety and efficacy profiles in pediatric patients as in adults

Effects on Hepatic and Renal Insufficiency

• No dosage adjustment required for patients with mild-to-moderate hepatic insufficiency
• No dosage adjustment recommended for patients with renal insufficiency

Drug Interaction Studies

• Did not have clinically important effects on specified drug pharmacokinetics
• Used concomitantly with a wide range of commonly prescribed drugs without adverse interactions

Placental Cross-Dosage in Animals

• Crosses the placenta following oral dosing in rats and rabbits

Storage Guidelines

• Optimal storage conditions for maintaining product effectiveness

Product Chemistry

• Details of the molecular formula and chemical structure

Caution for Nursing Mothers

• Caution advised due to excretion in human milk

Overdose Management

• Usual supportive measures in the event of overdose

Dosage Instructions

• Specific dosages for different age groups including adults, adolescents, and pediatric patients

Therapeutic Class Information

• Belongs to the class of leukotriene receptor antagonists

Pregnancy Usage Caution

• Use during pregnancy only if clearly needed

Pregnancy Warnings

• Use of Montenaaf 10 mg Tablet in pregnant women should be avoided unless clearly needed

Pregnancy Safety

• Caution advised due to lack of adequate and well-controlled studies in pregnant women

Child Dosage Instructions

• Specific dosages for pediatric patients of different age groups

Elderly Usage

• Safety and efficacy similar to that in younger adults

Potential Overdose Symptoms

• Adverse experiences consistent with the safety profile of Montenaaf

Usual Supportive Measures

• Use of usual supportive measures in case of overdose

Adverse Reactions in Overdose

• Frequently occurring adverse experiences in case of overdosage

Medical Monitoring

• Appropriate clinical monitoring recommended for potent enzyme inducers

Use in Acute Exacerbations

• Therapy with Montenaaf can be continued during acute exacerbations of asthma

Avoidance of Substitution

• Should not be abruptly substituted for inhaled or oral corticosteroids

Effect Duration Information

• Effect lasts for an average duration of 24 hours

Effects on Aspirin Sensitivity

• Effective in improving airway function in asthmatics with known aspirin sensitivity

Inhibition of Bronchoconstrictor Response

• Not shown to truncate bronchoconstrictor response to aspirin in aspirin-sensitive asthmatic patients

Storage Precautions

• Guidelines for storing the product to maintain efficacy

Chemical Structure Visualization

• Visual representation of the chemical structure of Montelukast Sodium

Related Brands

• Aeron FT 4 mg (Dispersible Tablet) - healthcare-pharmaceuticals-ltd
• Aeron FT 5 mg (Dispersible Tablet) - healthcare-pharmaceuticals-ltd
• Aeron 10 mg (Tablet) - healthcare-pharmaceuticals-ltd
• Montinex 4 mg (Chewable Tablet) - beacon-pharmaceuticals-plc
• Montinex 5 mg (Chewable Tablet) - beacon-pharmaceuticals-plc